Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
79 hedge funds and large institutions have $411M invested in Eidos Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 28 reducing their positions, and 16 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
1% more funds holding
Funds holding: 78 → 79 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
2% less capital invested
Capital invested by funds: $418M → $411M (-$6.75M)
36% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.06M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.5M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$6.18M |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$5.55M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$27.4M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.06M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$3.42M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.08M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.01M |
EIDX Hedge Fund Activity: Q3 2019 in Review
79 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q3 2019, worth a combined $411M — down 1.6% from $418M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EIDX positions and 16 closed out — a net gain of 1 holder — while 18 added to existing stakes and 28 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.06M. The largest seller was Viking Global Investors, exiting entirely with an estimated $27.4M sold.
- 79 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q3 2019, up from 78 in Q2 2019.
- Funds reported $411M of Eidos Therapeutics, Inc. Common Stock stock for Q3 2019, down 1.6% quarter-over-quarter.
- 17 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q3 2019 and 16 closed out, a net change of +1 holder.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q3 2019 was Fidelity Investments, an estimated $8.06M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q3 2019 was Viking Global Investors, an estimated $27.4M sold.
Based on aggregated 13F filings for Q3 2019.